Riyaz Shah
About
Riyaz Shah is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology.
According to data from OpenAlex, Riyaz Shah has authored 48 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Pulmonary and Respiratory Medicine, 32 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in Riyaz Shah's work include Lung Cancer Treatments and Mutations (28 papers), Lung Cancer Research Studies (11 papers) and Colorectal Cancer Treatments and Studies (10 papers). Riyaz Shah is often cited by papers focused on Lung Cancer Treatments and Mutations (28 papers), Lung Cancer Research Studies (11 papers) and Colorectal Cancer Treatments and Studies (10 papers). Riyaz Shah collaborates with scholars based in United Kingdom, United States and Japan. Riyaz Shah's co-authors include Kenneth J. O’Byrne, James Chih‐Hsin Yang, Vera Hirsh, Martin Schüler, Tony Mok, Nobuyuki Yamamoto, Lecia V. Sequist, Wu‐Chou Su, Jaafar Bennouna and Michael Boyer and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Oncogene.
In The Last Decade
Riyaz Shah
44 papers receiving 3.8k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Riyaz Shah United Kingdom | 19 | 3.3k | 2.8k | 1.1k | 708 | 183 | 48 | 3.9k | ||
| Yuri Rukazenkov United Kingdom | 21 | 3.7k 1.1× | 3.0k 1.1× | 1.0k 0.9× | 945 1.3× | 171 0.9× | 55 | 4.1k | ||
| Dae Ho Lee South Korea | 27 | 2.9k 0.9× | 2.4k 0.9× | 940 0.8× | 587 0.8× | 185 1.0× | 91 | 3.4k | ||
| Marcelo Marotti United Kingdom | 14 | 2.7k 0.8× | 2.1k 0.8× | 878 0.8× | 747 1.1× | 173 0.9× | 29 | 3.2k | ||
| Chong‐Rui Xu China | 27 | 3.5k 1.1× | 3.1k 1.1× | 1.0k 0.9× | 931 1.3× | 220 1.2× | 122 | 4.4k | ||
| Victoria Zazulina United Kingdom | 14 | 3.9k 1.2× | 3.4k 1.2× | 1.7k 1.5× | 882 1.2× | 245 1.3× | 23 | 4.7k | ||
| Maximiliano Van Kooten Argentina | 9 | 3.7k 1.1× | 3.3k 1.2× | 1.1k 1.0× | 623 0.9× | 171 0.9× | 14 | 4.5k | ||
| Willemijn S.M.E. Theelen Netherlands | 16 | 3.3k 1.0× | 3.0k 1.1× | 998 0.9× | 873 1.2× | 172 0.9× | 33 | 4.4k | ||
| Zofia Piotrowska United States | 26 | 2.1k 0.6× | 1.7k 0.6× | 938 0.8× | 541 0.8× | 199 1.1× | 122 | 2.6k | ||
| Hong‐Hong Yan China | 31 | 2.8k 0.9× | 2.5k 0.9× | 870 0.8× | 866 1.2× | 197 1.1× | 133 | 3.7k | ||
| Jordi Remón France | 34 | 2.4k 0.7× | 2.1k 0.8× | 1.0k 0.9× | 977 1.4× | 274 1.5× | 175 | 3.7k |
Countries citing papers authored by Riyaz Shah
Since
Specialization
Citations
This map shows the geographic impact of Riyaz Shah's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Riyaz Shah with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Riyaz Shah more than expected).
Fields of papers citing papers by Riyaz Shah
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Riyaz Shah. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Riyaz Shah. The network helps show where Riyaz Shah may publish in the future.
Co-authorship network of co-authors of Riyaz Shah
This figure shows the co-authorship network connecting the top 25 collaborators of Riyaz Shah. A scholar is included among the top collaborators of Riyaz Shah based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Riyaz Shah. Riyaz Shah is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Balaji, V., Andrew Katumba, Iosif Mporas, et al.. (2025). 3P Predicting immunotherapy-related adverse events in melanoma patients using machine learning algorithms and explainable artificial intelligence. ESMO Open. 10. 104158–104158.
2.
Chmielecki, Juliann, Jhanelle E. Gray, Ying Cheng, et al.. (2023). Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nature Communications. 14(1). 1070–1070.
3.
Banna, Giuseppe Luigi, Alfredo Addeo, Panagiota Zygoura, et al.. (2022). A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9–15 PROMISE-meso phase III trial. Lung Cancer. 169. 77–83.
4.
Shah, Riyaz, Nicolas Girard, Saurabh Nagar, et al.. (2021). European and US Real-World Treatment Patterns in Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Retrospective Medical Record Review. Drugs - Real World Outcomes. 8(4). 537–545.
5.
Middleton, Gary, Kristian Brock, Joshua Savage, et al.. (2020). Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial. The Lancet Respiratory Medicine. 8(9). 895–904.
6.
Shah, Riyaz & J.F. Lester. (2019). Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non–Small-Cell Lung Cancer: A Clash of the Generations. Clinical Lung Cancer. 21(3). e216–e228.
7.
Ramalingam, Suresh S., Yi Cheng, C. Zhou, et al.. (2018). Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study. Annals of Oncology. 29. viii740–viii740.
8.
Cho, Byoung Chul, Changdong Zhou, Fumio Imamura, et al.. (2018). Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study. Annals of Oncology. 29. ix177–ix177.
9.
Ferry, David, Lucinda Billingham, Hugh Jarrett, et al.. (2017). Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial. European Journal of Cancer. 83. 302–312.
10.
Woll, Penella J., Piers Gaunt, Nicola Steele, et al.. (2017). P1.07-015 STOMP: A UK National Cancer Research Network Randomised, Double Blind, Multicentre Phase II Trial of Olaparib as Maintenance Therapy in SCLC. Journal of Thoracic Oncology. 12(1). S704–S705.
11.
Popat, Sanjay, Laura Hughes, Mary O’Brien, et al.. (2017). P3.02b-046 Afatinib Benefits Patients with Confirmed/Suspected EGFR Mutant NSCLC, Unsuitable for Chemotherapy (TIMELY Phase II Trial). Journal of Thoracic Oncology. 12(1). S1215–S1216.
12.
Talbot, Toby, Adam Dangoor, Riyaz Shah, et al.. (2017). The burden of neutropenic sepsis in patients with advanced non-small cell lung cancer treated with single-agent docetaxel: A retrospective study. Lung Cancer. 113. 115–120.
13.
Schüler, Martin, James Chih‐Hsin Yang, Lecia V. Sequist, et al.. (2016). 138PD: Impact of dose adjustment on the safety and efficacy of afatinib in patients (pts) with advanced EGFR mutation-positive non-small cell lung cancer (NSCLC): Post-hoc analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6). Journal of Thoracic Oncology. 11(4). S116–S117.
14.
Lal, Rohit, Gunnar Hillerdal, Riyaz Shah, et al.. (2015). Feasibility of home delivery of pemetrexed in patients with advanced non-squamous non-small cell lung cancer. Lung Cancer. 89(2). 154–160.
15.
Sequist, Lecia V., James Chih‐Hsin Yang, Nobuyuki Yamamoto, et al.. (2013). Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations. Journal of Clinical Oncology. 31(27). 3327–3334.
16.
Papa, Sophie, Sanjay Popat, Riyaz Shah, et al.. (2013). Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy. Journal of Thoracic Oncology. 8(6). 783–787.
17.
Nicolson, M., Dean A. Fennell, David Ferry, et al.. (2013). Thymidylate Synthase Expression and Outcome of Patients Receiving Pemetrexed for Advanced Nonsquamous Non–Small-Cell Lung Cancer in a Prospective Blinded Assessment Phase II Clinical Trial. Journal of Thoracic Oncology. 8(7). 930–939.
18.
Minchom, Anna, et al.. (2010). An Unusual Case of Pancreatic Cancer with Leptomeningeal Infiltration. Journal of Gastrointestinal Cancer. 41(2). 107–109.
19.
Ang, Joo Ern, Riyaz Shah, Ian Coombes, et al.. (2009). A feasibility study of sequential doublet chemotherapy comprising carboplatin–doxorubicin and carboplatin–paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma. Annals of Oncology. 20(11). 1787–1793.
20.
Shah, Riyaz, Tanya Ahmad, & Tim Eisen. (2004). Treatment of recurrent or metastatic renal cell carcinoma. Expert Review of Anticancer Therapy. 4(6). 1069–1080.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Yuri Rukazenkov Breakdown of academic impact, for papers by Dae Ho Lee Breakdown of academic impact, for papers by Marcelo Marotti Breakdown of academic impact, for papers by Chong‐Rui Xu Breakdown of academic impact, for papers by Victoria Zazulina Breakdown of academic impact, for papers by Maximiliano Van Kooten Breakdown of academic impact, for papers by Willemijn S.M.E. Theelen Breakdown of academic impact, for papers by Zofia Piotrowska Breakdown of academic impact, for papers by Hong‐Hong Yan Breakdown of academic impact, for papers by Jordi Remón